Can CBD Cause a Positive Urine THC Test? The Product Composition Matters

"CBD use" is not a complete exposure history.

One product may contain purified cannabidiol with no measurable delta-9-tetrahydrocannabinol. Another may be a CBD-dominant cannabis extract containing a small but real quantity of delta-9 THC. Both may be marketed as CBD, but they do not create the same risk of a positive urine cannabinoid test.

A 2022 controlled-administration study in the Journal of Analytical Toxicology examined urine after oral and vaporized CBD and after vaporized CBD-dominant cannabis containing both CBD and delta-9 THC. The results separated two questions that are often blurred together:

1. Does administered CBD convert into delta-8 or delta-9 THC in the human body?
2. Can a CBD-labeled product that already contains delta-9 THC produce a positive urine test?

Under the study conditions, the investigators found no evidence that pure CBD converted to delta-8 or delta-9 THC. But the CBD-dominant cannabis material contained 3.7 milligrams of delta-9 THC, and some participants produced urine results capable of meeting commonly used screening and confirmation thresholds.

What the controlled study tested

Eighteen healthy adults completed controlled dosing sessions on a residential research unit. The study compared several conditions, including 100 milligrams of oral CBD, 100 milligrams of vaporized CBD, placebo, and vaporized CBD-dominant cannabis containing 100 milligrams of CBD plus 3.7 milligrams of delta-9 THC.

The oral CBD was supplied in three formulations: a capsule, a pharmacy-grade syrup, and Epidiolex. Urine was collected before dosing and for 58 hours afterward. Investigators used cannabinoid immunoassay screening at 20, 50, and 100 ng/mL cutoffs and LC-MS/MS quantitation for individual cannabinoids and metabolites.

This controlled design is stronger than relying on a consumer's product label alone. The administered doses and formulations were known, the participants were monitored, and the urine specimens were tested by defined methods. It still represents a limited acute-dosing experiment, not every pattern of retail-product use.

For background on the specimen, see Urine Toxicology Interpretation and Detection Windows in Toxicology.

Pure CBD did not produce a federal-cutoff positive in this study

Across the conditions in which CBD alone was administered, the investigators reported no evidence that CBD converted to delta-8 or delta-9 THC. All 702 urine specimens from those pure-CBD conditions were true negatives at the 50 and 100 ng/mL immunoassay cutoffs for delta-9-THCCOOH.

That finding directly addresses the conversion theory under the tested conditions. Earlier laboratory experiments had reported that CBD could degrade to THC in simulated acidic fluids. The controlled human study did not reproduce that conversion after oral or vaporized pure CBD across the formulations examined.

The result should be stated precisely. It does not prove that every product sold as pure CBD contains no THC. It shows that the known pure-CBD administrations in this experiment did not produce the tested urine pattern through in-vivo conversion.

CBD-dominant cannabis was different because it contained THC

The CBD-dominant cannabis condition delivered 100 milligrams of CBD and 3.7 milligrams of delta-9 THC. After that exposure, three of the 18 participants produced six urine specimens with delta-9-THCCOOH concentrations at or above 15 ng/mL.

All six of those specimens screened positive at the 20 ng/mL immunoassay cutoff. Two screened positive at the 50 ng/mL cutoff. The study concluded that vaporizing the tested CBD-dominant material could produce a positive result at the 50 ng/mL screening and 15 ng/mL confirmation cutoffs referenced in federal workplace testing.

The critical cause was not a demonstrated conversion of CBD into THC. The administered material already contained delta-9 THC. Once delta-9 THC entered the body, formation and urinary excretion of delta-9-THCCOOH were expected metabolic events.

See Cannabis Metabolites in Toxicology for the distinction between the parent compound and the urine metabolite.

A positive result does not identify the product

A confirmed urine delta-9-THCCOOH result supports exposure to delta-9 THC. It does not, by itself, identify whether the THC came from marijuana, a hemp-derived extract, a mislabeled product, a lawful medication, or another source.

Nor does the urine concentration reconstruct the exact dose or time of use. Hydration, specimen timing, frequency of prior use, body composition, metabolism, and the product's actual cannabinoid content can all affect the observed concentration.

A forensic review should therefore distinguish analytical identification from source attribution. The laboratory may reliably identify delta-9-THCCOOH while lacking any basis to identify the commercial product that produced it. Product attribution requires evidence outside the urine result, such as purchase records, packaging, batch-specific testing, retained product, and a credible use history.

Screening and confirmation answer different questions

An immunoassay is a class-oriented screen. It indicates that antibody response exceeded a cutoff, but it does not provide the molecular specificity of a properly validated chromatographic mass-spectrometric method.

The Sholler study used multiple screening cutoffs and LC-MS/MS quantitation. That distinction shows why the numerical cutoff and testing stage must be identified before calling a sample positive. A specimen may exceed a lower screening threshold but not a higher one. Confirmation then applies its own analyte-specific threshold and identification criteria.

See Immunoassay Screening, Confirmatory Drug Testing, and Toxicology Reporting Cutoffs.

Limits of the study

The study involved 18 healthy adults and acute administration. The CBD-dominant material contained 0.39 percent delta-9 THC by dry weight, slightly above the federal hemp threshold discussed in the article. Only one batch of CBD-dominant cannabis, one vaporizer type, and one CBD/THC dose were evaluated.

The authors also reported low cannabinoid concentrations in some baseline samples between sessions, suggesting that a longer washout period might be needed in future work. Repeated daily use, different formulations, different product composition, and ordinary variation in urine dilution could produce different results.

These limits do not erase the observed findings. They define what can reasonably be generalized. The study demonstrates that a CBD-dominant product containing a small measured THC dose can produce positive urine results in some people. It does not supply a universal probability for every CBD product or user.

Records needed to evaluate a disputed CBD-related result

A case-specific review should request:

1. The screening assay, manufacturer, reagent lot, cutoff, raw signal, controls, and package insert.
2. The confirmation method, analytes, reporting limits, chromatograms, ion ratios, retention times, calibrators, controls, and audit trail.
3. The collection time, specimen validity results, creatinine, specific gravity, and chain of custody.
4. The complete history of cannabis, hemp, CBD, prescription, supplement, and over-the-counter product use.
5. The product label, certificate of analysis, batch or lot number, purchase source, and date of use.
6. Any retained product for independent quantitative cannabinoid testing.
7. The dose, route, frequency, duration, and timing of claimed product use.
8. Prior and subsequent test results interpreted with their collection times and cutoffs.
9. The laboratory's policy for presumptive positives, confirmation, and amended reports.
10. Evidence supporting any opinion that the urine concentration identifies a specific product or time of exposure.

Without product-specific evidence, the word "CBD" may conceal the most important fact: whether the administered material contained delta-9 THC.

The bottom line

Pure CBD and CBD-dominant cannabis containing delta-9 THC are analytically different exposures. In the controlled study, pure CBD did not show conversion to delta-8 or delta-9 THC and did not produce positives at the tested federal screening cutoff. The CBD-dominant cannabis material already contained 3.7 milligrams of delta-9 THC, and some participants produced urine results meeting commonly used screening and confirmation thresholds.

A confirmed urine THC-metabolite result may support delta-9 THC exposure, but it does not identify the specific product, dose, or time of use. Those conclusions require additional evidence.

Primary source

Sholler DJ, Spindle TR, Cone EJ, Goffi E, Kuntz D, Mitchell JM, Winecker RE, Bigelow GE, Flegel RR, Vandrey R. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Delta-9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. Journal of Analytical Toxicology. 2022;46(5):494-503. PubMed record. PubMed Central full-text record. Oxford Academic journal record. doi:10.1093/jat/bkab059.

For a broader framework for interpreting cannabinoid evidence, see Cannabis & THC Forensic Toxicology.

Editorial note: This article paraphrases the published research. Do not upload or reproduce the source PDF, publisher layout, tables, or figures.